Comparative Effects of Alpha Lipoic Acid and Melatonin on Cisplatin-Induced Neurotoxicity

REFERENCES

• Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008). Cisplatin: A review of toxicities and therapeutic applications [Review]. Veterinary and Comparative Oncology, 6(1), 1–18.
   PubMed Web of Science ®Google Scholar
• Cavaletti, G., Cascinu, S., Venturino, P., Tedeschi, M., & Tredici, G. (1996). Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Research, 16(5B), 3149–3159.
   PubMed Web of Science ®Google Scholar
• Cavaletti, G., & Marmiroli, P. (2004). Chemotherapy-induced peripheral neurotoxicity [Review]. Expert Opinion on Drug Safety, 3(6), 535–546.
   PubMedGoogle Scholar
• Cummins, K. L., Dorfman, L. J., & Perkel, D. H. (1979a). Nerve fiber conduction velocity distributions. I. Estimation based on the single-fiber and compound action potentials. Electroencephalography and Clinical Neurophysiology, 46, 634–646.
   PubMedGoogle Scholar
• Cummins, K. L., Dorfman, L. J., & Perkel, D. H. (1979b). Nerve fiber conduction velocity distribution. II. Estimation based on two compound action potentials. Electroencephalography and Clinical Neurophysiology, 46, 647–658.
   PubMedGoogle Scholar
• Dalkilic, N., & Pehlivan, F. (2002a). Comparison of fiber diameter distribution deduced by modelling compound action potentials recorded by extracellular and suction techniques. International Journal of Neuroscience, 112, 913–930.
   PubMed Web of Science ®Google Scholar
• Dalkilic, N., & Pehlivan F. (2002b). A correction procedure for the volume conductor effect in the compound action potential recorded from isolated nerve trunk. International Journal of Neuroscience, 112, 1013–1026.
   PubMed Web of Science ®Google Scholar
• Dalkilic, N., Tuncer, S., Bariskaner, H., & Kiziltan, E. (2009). Effect of tramadol on the rat sciatic nerve conduction: A numerical analysis and conduction velocity distribution study. Yakugaku Zasshi, 129(4), 485–493.
   Google Scholar
• Delisa, J. A., Lee, H. J., Baran, E. M., Lai, K.-S., & Spielholz, N. (1994). Manual of nerve conduction velocity and clinical neurophysiology. New York: Raven.
   Google Scholar
• Kedar, A., Cohen, M. E., & Freeman, A. I. (1978). Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: A case report. Cancer Treatment Reports, 62(5), 819–821.
   Google Scholar
• Kiziltan, E., Dalkilic, N., Guney, F. B., & Pehlivan, F. (2007). Conduction velocity distribution: Early diagnostic tool for peripheral neuropathies. International Journal of Neuroscience, 117(2), 203–213.
   PubMed Web of Science ®Google Scholar
• Krarup, C. (2004). Compound sensory action potential in normal and pathological human nerve. Muscle & Nerve, 29, 465–483.
   PubMed Web of Science ®Google Scholar
• Mantovani, G., Maccio, A., Madeddu, C., Mura, L., Gramignano, G., Lusso, M. R., (2003). The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: Correlation with disease progression. Free Radical Research, 37, 213–223.
   PubMed Web of Science ®Google Scholar
• Melli, G., Taiana, M., Camozzi, F., Triolo, D., Podini P., Quattrini, A., (2008). Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Experimental Neurology, 214(2), 276–284.
   PubMed Web of Science ®Google Scholar
• Packer, L. (1998). Alpha-Lipoic acid: A metabolic antiaoxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metabolism Reviews, 30(2), 245–275.
   PubMed Web of Science ®Google Scholar
• Papadopolulou, F. A., & Panas, S. M. (1999). Bispectral de-noising of the compound action potential for estimation of the nerve conduction velocity distribution. Medical Engineering & Physics, 21, 499–503.
   PubMedGoogle Scholar
• Pehlivan, F. (1997). Biyofizik [Biophysics]. Ankara, Turkey: Hacettepe-Tas Kitapcilik.
   Google Scholar
• Peltier, A. C., & Russell, J. W. (2002). Recent advances in drug-induced neuropathies. Current Opinion in Neurology, 15, 633–638.
   PubMed Web of Science ®Google Scholar
• Peterson, G. W., & Will, A. D. (1988). Newer electrodiagnostic techniques in peripheral nerve injuries [Review]. Current Opinion in Neurology, 19(1), 13–25.
   Google Scholar
• Reiter, R. J., Tan, D. X., Sainz, R. M., Mayo, J. C., & Lopez-Burillo, S. (2002). Melatonin: Reducing the toxicity and increasing the efficacy of drugs. Journal of Pharmacy and Pharmacology, 54, 1299–1321.
   PubMed Web of Science ®Google Scholar
• Ritter, A. M., Ritchie, C., & Martin, W. J. (2007). Relationship between the firing frequency of injured peripheral neurons and inhibition of firing by sodium channel blockers. Journal of Pain, 8(4), 287–295.
   Google Scholar
• Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007). Mechanisms of cisplatin-induced ototoxicity and prevention. Hearing Research, 226(1–2), 157–167.
   PubMed Web of Science ®Google Scholar
• Schoonhoven, R., & Stegeman, D. F. (1991). Models and analysis of compound nerve action potentials [Review]. Critical Reviews in Biomedical Engineering, 19(1), 47–111.
   PubMed Web of Science ®Google Scholar
• Sioka, C., & Kyritsis, A. P. (2009). Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 63(5), 761–767.
   PubMed Web of Science ®Google Scholar
• Somani, S. M., Husain, K., Whitworth, C., Trammell, G. L., Malafa, M., & Rybak, L. P. (2000). Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. Pharmacology & Toxicology, 86, 234–241.
   PubMedGoogle Scholar
• Taylor, P. K. (1993). CMAP dispersion, amplitude decay, and area decay in a normal population. Muscle & Nerve, 16, 1181–1187.
   PubMedGoogle Scholar
• Tomaszewski, A., & Büsselberg, D. (2007). Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology, 28(1), 49–58.
   Google Scholar
• von Schlippe, M., Fowler, C. J., & Harland, S. J. (2001). Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: Time course and prognosis. British Journal of Cancer, 85(6), 823–826.
   PubMedGoogle Scholar
• Wang, J., He, D., Zhang, Q., Han, Y., Jin, S., & Qi, F. (2009). Resveratrol protects against Cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biotherapy & Radiopharmaceuticals, 24(6), 675–680.
   Google Scholar
• Yoshida, M., Fukuda, A., Hara, M., Terada, A., Kitanaka, Y., & Owada, S. (2003). Melatonin prevents the increase in hydroxyl radical-spin trap adduct formation caused by the addition of cisplatin in vitro. Life Sciences, 72, 1773–1780.
   PubMed Web of Science ®Google Scholar